Investors hated the fact that MYRX was buying JAV with stock that was trading for well under net cash. Also, the deal was a grab to complete MYRX's self-fulfilling prophecy of being a "real" pharmaceutical company. It never made any sense- no fit with their other products which are in cancer and HIV, and they would have spent a huge amount of money to create a commercial infrastructure to sell a product with a modest market at best. They also had no intention of developing JAV's other two late stage pain candidates. Hospira is a much better fit and can fold in JAV will little effort it would seem. MYRX stock will take another huge hit is they raise their bid which I think is highly unlikely.
Market Data 
Markets 
AI
